IN VIVO Blog picked up on a few things you may have missed over Father's Day weekend.
- The NYT magazine ran a cover story on the fine line between drug prescriber and drug pusher for particularly aggressive pain-management physicians.
- Drugs for pulmonary arterial hypertension (PAH) were front and center at FDA. The agency approved Gilead's ambrisentan (Letairis) and (again) rejected Encysive's sitaxsentan (Thelin). Gilead landed US rights to Letairis via its $2.2 bb acquisition of Myogen last year; the drug could soon start picking up market share from Actelion's bosentan (Tracleer).
- JNJ is blogging. GSK is blogging. But why? (Hat tips: Pharmalot and Pharmagossip)
- Finally, private equity continued its inexorable push into biotech companies yesterday as Lexicon Pharmaceuticals announced it would take on $205 million investment from The Invus Group (which may pour in an additional $345 million over the next four years) and $60 million from Symphony Capital. More on this later ...